Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
174 stopped studies mapped to T-Cell Non-Hodgkin Lymphoma and descendants · 84% state a reason
Over the 174 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02440685 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid… | Phase 1 / Phase 2 | terminated | May 12, 2015 | Asana BioSciences | Business decision | Sponsor / business decision |
| NCT01579318 | Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma(CTCL) | Phase 2 | terminated | Apr 17, 2012 | OncoSec Medical Incorporated | Due to company resource constraints | Sponsor / business decision |
| NCT03999658 | A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected… | Phase 2 | withdrawn | Jun 27, 2019 | Sorrento Therapeutics, Inc. | Sorrento Therapeutics filed for chapter 11 bankruptcy. | Other (stated, no rule matched) |
| NCT02890368 | Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory… | Phase 1 | terminated | Sep 7, 2016 | Pfizer | not stated | Not stated |
| NCT04602065 | Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory… | Phase 1 / Phase 2 | terminated | Oct 26, 2020 | Innovent Biologics (Suzhou) Co. Ltd. | Due to the company's development strategy adjustment, Innovent Biologics has decided not to… | Sponsor / business decision |
| NCT05513612 | Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies | Phase 1 | withdrawn | Aug 24, 2022 | Shanghai Pudong Hospital | The study is not initiated and we want it to be withdrawn. | Other (stated, no rule matched) |
| NCT04021082 | CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory… | Phase 2 / Phase 3 | withdrawn | Jul 16, 2019 | Portola Pharmaceuticals | Sponsor decision to not initiate the trial | Sponsor / business decision |
| NCT04334174 | Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster…(BRENTICON-T) | Phase 2 | withdrawn | Apr 6, 2020 | University of Kansas Medical Center | accrual not met | Enrollment / accrual |
| NCT01746173 | CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma | Phase 2 | terminated | Dec 10, 2012 | Dana-Farber Cancer Institute | Slow accrual and futility | Efficacy / futility |
| NCT02314247 | Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell… | Phase 2 | terminated | Dec 11, 2014 | Karyopharm Therapeutics Inc | Due to enrollment challenges | Enrollment / accrual |
| NCT01028716 | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic… | Phase 2 | terminated | Dec 9, 2009 | Fred Hutchinson Cancer Center | The study experienced lower accrual rates after the onset of COVID. Upon review of the collected… | COVID-19 / pandemic |
| NCT01712659 | Ruxolitinib for Adult T-Cell Leukemia | Phase 1 / Phase 2 | terminated | Oct 23, 2012 | National Cancer Institute (NCI) | The adult T-cell leukemia (ATL) research program was terminated after the death of the T-cell… | Investigator |
| NCT04860817 | A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and… | Early Phase 1 | withdrawn | Apr 27, 2021 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | No proper participant is found. | Other (stated, no rule matched) |
| NCT04639843 | Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell… | Phase 1 | withdrawn | Nov 23, 2020 | National Cancer Institute (NCI) | Safety issues with PI3 kinase inhibitors | Safety / toxicity |
| NCT02811783 | Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of… | Phase 3 | terminated | Jun 23, 2016 | Elorac, Inc. | Sponsor decision | Sponsor / business decision |
| NCT04444141 | A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell… | Phase 1 / Phase 2 | terminated | Jun 23, 2020 | Akeso | Due to difficuty of erollment and consideration of clinical guideline,The sponsor decided to stop… | Sponsor / business decision |
| NCT05239910 | Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front… | Phase 2 | withdrawn | Feb 15, 2022 | Rhizen Pharmaceuticals SA | Change in development plan | Other (stated, no rule matched) |
| NCT02572453 | Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL | Phase 2 | terminated | Oct 9, 2015 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT05156229 | A Phase 1/2a Study of CDK-003 in Patients With Cutaneous T-Cell Lymphoma (CTCL).(Part B) | Phase 1 | terminated | Dec 14, 2021 | Codiak BioSciences | PK/PD from two patients plus the healthy volunteer data confirmed the RP2D and manageable safety… | Safety / toxicity |
| NCT04973527 | LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor | Phase 1 | terminated | Jul 22, 2021 | Beijing Boren Hospital | Both the sponsors and collaborator are considering terminating the study | Other (stated, no rule matched) |
| NCT03713320 | SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With…(SOLAR) | Phase 2 | terminated | Oct 19, 2018 | miRagen Therapeutics, Inc. | The study was terminated early for business reasons, and not due to concerns regarding safety or… | Safety / toxicity |
| NCT01685606 | Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight…(273) | Phase 2 | terminated | Sep 14, 2012 | Brown University | Lack of accrual and low efficacy | Efficacy / futility |
| NCT02323659 | Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous… | Phase 4 | terminated | Dec 23, 2014 | Polish Lymphoma Research Group | Slow recruitment | Enrollment / accrual |
| NCT00476554 | A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous… | Phase 2 | terminated | May 22, 2007 | Cyclacel Pharmaceuticals, Inc. | slow accrual and financial resource limitation | Enrollment / accrual |
| NCT01420679 | Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral… | Phase 3 | terminated | Aug 22, 2011 | Spectrum Pharmaceuticals, Inc | not stated | Not stated |
| NCT01805037 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+… | Phase 1 / Phase 2 | terminated | Mar 5, 2013 | Northwestern University | Lack of funding | Funding |
| NCT00490776 | Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell… | Phase 2 | terminated | Jun 25, 2007 | Novartis Pharmaceuticals | Recruitment was stopped on 15 June 2009 (early termination date) due to low prevalence of study… | Enrollment / accrual |
| NCT01644253 | Phase 1b Safety and Efficacy Study of TRU-016 | Phase 1 | terminated | Jul 19, 2012 | Aptevo Therapeutics | Business decision | Sponsor / business decision |
| NCT03154710 | Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of… | N/A | terminated | May 16, 2017 | Weprom | Negative interim analysis | Efficacy / futility |
| NCT02301494 | Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma(CTCL) | N/A | withdrawn | Nov 26, 2014 | Rochester General Hospital | No participants were enrolled in the study. | Enrollment / accrual |
| NCT02341209 | Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma(CTCL) | Phase 2 | terminated | Jan 19, 2015 | Rochester General Hospital | Low enrollment | Enrollment / accrual |
| NCT01678443 | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With… | Phase 1 | terminated | Sep 5, 2012 | Fred Hutchinson Cancer Center | Terminated due to low accrual. | Enrollment / accrual |
| NCT03719898 | Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma | Phase 2 | withdrawn | Oct 25, 2018 | Fox Chase Cancer Center | Slow accrual | Enrollment / accrual |
| NCT03837457 | PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who…(PRISM) | Phase 2 | terminated | Feb 12, 2019 | miRagen Therapeutics, Inc. | Study no longer needed because eligible subjects may receive treatment with cobomarsen in a… | Other (stated, no rule matched) |
| NCT04230330 | Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma | Phase 1 | withdrawn | Jan 18, 2020 | National Cancer Centre, Singapore | PI has left the institution. | Other (stated, no rule matched) |
| NCT03553914 | PLM60 for Peripheral T Cell Lymphoma (PTCL) | Phase 1 / Phase 2 | withdrawn | Jun 12, 2018 | Conjupro Biotherapeutics, Inc. | IND Inactive Status | Other (stated, no rule matched) |
| NCT03925428 | Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and… | Phase 1 | withdrawn | Apr 24, 2019 | National Cancer Institute (NCI) | Other - Protocol moved to Disapproved | Other (stated, no rule matched) |
| NCT04233697 | Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature… | Phase 1 | withdrawn | Jan 18, 2020 | Columbia University | Investigator left institution | Investigator |
| NCT00632827 | Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using… | Phase 2 | terminated | Mar 11, 2008 | University of California, San Francisco | Manufacturing shortage of both Diftitox and Doxil | Drug supply |
| NCT03617224 | Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary… | Phase 1 | withdrawn | Aug 6, 2018 | University of Texas Southwestern Medical Center | Unable to enroll patients that met enrollment criteria. | Enrollment / accrual |
| NCT03075553 | Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | Phase 2 | terminated | Mar 9, 2017 | Mayo Clinic | due to poor response | Other (stated, no rule matched) |
| NCT00860171 | Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating… | Phase 1 | terminated | Mar 12, 2009 | Fred Hutchinson Cancer Center | Terminated due to lack of funding | Funding |
| NCT01609816 | Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for… | Phase 1 | terminated | Jun 1, 2012 | Barbara Ann Karmanos Cancer Institute | Low accrual. No Analyses were performed | Enrollment / accrual |
| NCT01742793 | An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid)…(RID) | Phase 1 | terminated | Dec 5, 2012 | Yale University | The study was terminated due to withdrawal of institutional support, Phase II never began. | Other (stated, no rule matched) |
| NCT02465528 | Ceritinib Rare Indications Study in ALK+ Tumors | Phase 2 | terminated | Jun 8, 2015 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT01445340 | Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma | Phase 1 | terminated | Oct 3, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00655668 | A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory…(EXPECT) | Phase 2 | terminated | Apr 10, 2008 | Celgene | Decision not to pursue as single agent in the study population. | Other (stated, no rule matched) |
| NCT02087878 | A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel…(HSTCL) | — | withdrawn | Mar 14, 2014 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT03195010 | Management of Platelet Transfusion Therapy in Patients With Blood Cancer or… | Phase 2 | terminated | Jun 22, 2017 | Fred Hutchinson Cancer Center | Terminated because of slow recruitment and lack of funding support | Enrollment / accrual |
| NCT02729961 | Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic… | Phase 1 / Phase 2 | withdrawn | Apr 6, 2016 | University of Washington | Administrative closure | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jun 7, 2023source: clinicaltrials